DoW Arthritis Translational Research Award
Defense Health Agency Contracting Activity - DHACA · Military Medical Research and Development (12.420)
Posted 1 May 2026 · 21 days left
In plain terms
The US Defense Health Agency funds high-impact translational arthritis research that moves basic findings toward clinical solutions for Service Members and Veterans, with preclinical or animal studies allowed but not clinical trials. Applications from any entity type are welcome, with a total programme budget of 1.6 million US dollars, and must be submitted by 22 October 2026.
A generated summary of the donor's text; the original wording is below.
Summary
Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to Service Members, Veterans, their Families and the American public. Research addressing any and all types of arthritis is encouraged.
Distinctive Features: The FY26 ATRP TRA mechanism is intended to support preclinical or animal research and may not be used for clinical research or clinical trials. Basic research, as defined in Section 3.1.2, is not allowed. A key aspect of this award mechanism is impact. The application should explicitly state how outcomes of the proposed research will significantly advance arthritis research, particularly in accelerating critical findings into clinically relevant solutions.
Preliminary and/or published data, originating from research conducted by the applicant(s) or others, is required.
Excerpt from the donor's page. The full text, annexes and forms are on the original call.
Who can apply
- ngo_cso
- academia_research
- private_company
- government
- individual
Eligibility and conditions
Show the eligibility text from the source
Applicant types: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"